Hyperglycemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hyperglycemia stocks.

Hyperglycemia Stocks Recent News

Date Stock Title
Nov 1 DXCM DexCom (DXCM) Fell Due to an Uncharacteristic Earnings Miss
Nov 1 CORT Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?
Nov 1 MNKD MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
Nov 1 CORT Corcept’s relacorilant GRADIENT trial misses primary endpoint
Nov 1 CORT Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Oct 31 MNKD MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
Oct 31 CORT Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Oct 31 CORT Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
Oct 31 CORT Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript
Oct 31 MNKD First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
Oct 30 CORT Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates
Oct 30 CORT Corcept: Q3 Earnings Snapshot
Oct 30 CORT Corcept Therapeutics GAAP EPS of $0.41 beats by $0.13, revenue of $182.5M beats by $10.53M
Oct 30 CORT Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
Oct 30 DXCM Is DexCom, Inc. (NASDAQ:DXCM) The Worst Performing S&P 500 Stock In 2024?
Oct 30 DXCM Here’s Why DexCom (DXCM) Detracted in Q3
Oct 30 DXCM Multiple Headwinds Dragged DexCom (DXCM) in Q3
Oct 29 CORT Corcept Therapeutics Q3 2024 Earnings Preview
Oct 28 DXCM Here's Why DexCom (DXCM) is a Strong Momentum Stock
Oct 28 DXCM These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Hyperglycemia

Hyperglycemia (also spelled hyperglycaemia or hyperglycæmia), also known as high blood sugar, is a condition in which an excessive amount of glucose circulates in the blood plasma. This is generally a blood sugar level higher than 11.1 mmol/l (200 mg/dl), but symptoms may not start to become noticeable until even higher values such as 15–20 mmol/l (~250–300 mg/dl). A subject with a consistent range between ~5.6 and ~7 mmol/l (100–126 mg/dl) (American Diabetes Association guidelines) is considered slightly hyperglycemic, while above 7 mmol/l (126 mg/dl) is generally held to have diabetes. For diabetics, glucose levels that are considered to be too hyperglycemic can vary from person to person, mainly due to the person's renal threshold of glucose and overall glucose tolerance. On average however, chronic levels above 10–12 mmol/L (180–216 mg/dl) can produce noticeable organ damage over time.

Browse All Tags